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Along with other childhood cancer survivors (CCS), hematopoietic cell transplantation (HCT) survivors are at
high risk of treatment-related late effects, including cardiovascular disease and diabetes. Cardiometabolic risk
factor abnormalities may be exacerbated by inadequate physical activity (PA). Relationships between PA and
cardiometabolic risk factors have not been well described in CCS with HCT. PA (self reported), mobility (timed
up and go test), endurance (6-minute walk test), handgrip strength, and cardiometabolic risk factors were
measured in 119 HCT survivors and 66 sibling controls ages 18 years. Adjusted comparisons between HCT
survivors and controls and between categories of low and high PA, mobility, endurance, and strength were
performed with linear regression. Among HCT survivors, the high PA group had lower waist circumference
(WC) (81.9  2.5 versus 88.6  3.1 cm  standard error (SE), P ¼ .009) than the low PA group, whereas the
high endurance group had lower WC (77.8  2.6 versus 87.8  2.5 cm  SE, P ¼ .0001) and percent fat mass
(33.6  1.8 versus 39.4  1.7%  SE, P ¼ .0008) and greater insulin sensitivity (IS) (10.9  1.0 versus 7.42 
1.14 mg/kg/min  SE via euglycemic insulin clamp, P ¼ .001) than the low endurance group. Differences were
greater in HCT survivors than in controls for WC between low and high PA groups, triglycerides between low
and high mobility groups, and WC, systolic blood pressure, and IS between low and high endurance groups
(all Pinteraction <.05). Higher endurance was associated with a more favorable cardiometabolic proﬁle in HCT
survivors, suggesting that interventions directed to increase endurance in survivors may reduce the risk of
future cardiovascular disease.
 2015 American Society for Blood and Marrow Transplantation.BACKGROUND effects, including cardiovascular disease, abdominal obesity,
Nearly 45 years after the ﬁrst successful allogeneic bone
marrow transplantation was conducted [1], hematopoietic
cell transplantation (HCT) has become a standard treatment
for a number of malignant and nonmalignant conditions in
children. As the number of transplantations performed has
increased, survival after HCT has been increasing, resulting in
a growing population of long-term survivors [2]. Unfortu-
nately, along with other childhood cancer survivors (CCS),
HCT survivors are at high risk for numerous adverse lateedgments on page 1282.




ty for Blood and Marrow Transplantation.insulin resistance, and diabetes mellitus [3-5]. Although the
etiology of these late effects is multifactorial and not well
understood, exposure to total body irradiation and other
forms of prolonged immunosuppressive treatment during
the HCT process and post-transplantation endocrine
dysfunction and/or leptin resistance have been suggested to
play a role [3,5,6].
In recent years, more attention has been placed on the
prevention of adverse late effects among CCS by lifestyle
behaviors, such as diet, physical activity (PA), and smoking
cessation. For example, physical inactivity is thought to
exacerbate several late effects, such as cardiovascular dis-
ease, abdominal visceral obesity, hypertension, dyslipidemia,
and insulin resistance [7-9]. Most studies have reported low
levels of PA among CCS, especially those who are now adults
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or meet guidelines for regular PA, and they are less likely to
be physically active compared with noncancer controls [10].
Perhaps more importantly, reduced cardiorespiratory
endurance (maximal oxygen uptake [VO2 max]), mobility,
and muscle strength have also been reported among adult
survivors of childhood cancer [11,12]. Such deﬁcits might
result from and/or contribute to low PA levels.
Among the general population, all cause mortality, car-
diovascular disease, dyslipidemia, insulin resistance, and
type 2 diabetes have all been shown to be inversely associ-
ated with PA [13,14]. In addition, greater cardiorespiratory
endurance and muscle strength have been inversely associ-
ated with several cardiometabolic risk factors [15-23]. Re-
lationships between PA/ﬁtness and cardiometabolic risk
factors among HCT survivors are not well understood; only 2
prior studies of HCT survivors have examined possible as-
sociations between PA and cardiometabolic risk factors and/
or outcomes [24,25]. Therefore, we examined cross-sectional
associations of PA and ﬁtness (ie, mobility, endurance, and
muscle strength) measures with cardiometabolic risk factors
among CCS who underwent HCT and their sibling controls.
METHODS
Study Design
The study was approved by the institutional review board human sub-
jects committees at the University of Minnesota and the Fred Hutchinson
Cancer Research Center/Seattle Cancer Care Alliance (FHCRC/SCCA). All
participants provided written informed consent. HCT survivors were
selected from transplantation databases at each institution andwere eligible
to participate if they were diagnosed with a primary hematologic malig-
nancy at age  21 years, received HCT, were treated at either Fairview-
University Medical Center or the FHCRC/SCCA, were  9 years of age at
the time of study participation, survived a minimum of 2 years after
transplantation, and were currently in remission. Sibling controls were
eligible to participate if they were  9 years of age at the time of exami-
nation and never had cancer. Controls were frequency matched to HCT
survivors by age and sex. Pregnant women were excluded until 3 or more
months after the end of their pregnancy. Of the 339 potentially eligible
survivors identiﬁed, 60 refused participation and we were unable to
establish contact (passive refusal) with an additional 125 subjects. The
remaining 154 (45% of those potentially eligible, 72% of those contacted)
provided informed written consent to participate along with 92 of their
siblings. Three HCT survivors were found to be ineligible at the time of study
because of previously undiagnosed diabetes (n ¼ 1), severe hypertension
(n ¼ 1), and multiple medical issues (n ¼ 1) that all required immediate
medical attention. This left the ﬁnal study population of 151 subjects. For the
purposes of this analysis, we excluded the 32 HCT survivors and 26 controls
who were younger than 18 years of age, leaving a total of 119 HCT survivors
and 66 controls.
Data Collection
All participants underwent a 2-day examination at the University of
Minnesota Clinical Research Center/Clinical and Translational Science
Institute or the Clinical Research Center at FHCRC/SCCA. Height, weight,
waist circumference (WC), and blood pressure were assessed according to a
standard protocol, as previously described [26]. Fat mass and lean bodymass
were measured using dual-energy X-ray absorptiometry (Lunar Prodigy
scanner, software version 9.3; General Electric Medical Systems, Madison,
WI).
After a 10- to 12-hour overnight fast, the hyperinsulinemic euglycemic
clamp method was used to assess insulin sensitivity (IS), as described pre-
viously [26,27]. Insulin infusion was started at time 0 at a rate of 1 mU/kg/
minute for 3 hours. An infusion of 20% glucose was given and adjusted to
maintain euglycemia (serum glucose level of 100 mg/dL [5.6 mmol/L]) with
plasma glucose determined every 10 minutes. IS was determined by the
amount of glucose required to maintain euglycemia in the ﬁnal 40 minutes
of the clamp study and expressed as mg/kg/minute of glucose with
adjustment for lean body mass. Lower IS values are indicative of greater
insulin resistance.
Fasting blood samples obtained at the start of the insulin clamp were
analyzed for serum lipid levels (low-density lipoprotein cholesterol [LDL-C],
high-density lipoprotein cholesterol [HDL-C], triglycerides), serum insulin,
and plasma glucose using a Vitros 5600 (Ortho-Clinical Diagnostics, Inc.,Rochester, NY), a chemoluminescence immunoassay (Immulite Insulin DPC,
Los Angeles, CA), and a Beckman Glucose Analyzer II (Beckman Instruments,
Fullerton, CA), respectively. LDL-C was calculated by the Friedewald equa-
tion. Homeostasis model assessment insulin resistance (HOMA-IR) was
calculated with fasting insulin and glucose values using the equation
HOMA-IR¼ ([fasting glucose units of mmol/L * insulin units in mU/mL]/22.5)
[28].
To assess PA, participants completed the Modiﬁable Activity Question-
naire. Participants reported activities in which they had participated at least
10 times during the past year in their leisure time, along with the number of
months over the year, the average number of times per month, and the
average minutes per time that each activity was performed. In addition,
participants reported averageminutes per day spent walking or bicycling to/
from work along with the number of days per week and months per year
they attended their job(s). The Modiﬁable Activity Questionnaire has been
shown to provide valid and reproducible estimates of past-year leisure-time
PA in adult populations [29,30].
A subset of participants (82 HCT survivors, 33 controls) completed
physical functioning assessments to objectively measure mobility, endur-
ance, and strength. Functional mobility was evaluated by the validated
“Timed Up and Go” measure [31], which is the time in seconds taken by an
individual to stand up from a 46 cm height arm chair, walk 3 meters, turn,
walk back to the chair, and sit down again. Endurance was measured by a
6-minute walking test (a validated modiﬁed Cooper test [32,33]), in which
the total distance (in meters) traveled in 6 minutes is recorded by a
pedometer. Handgrip strength was measured in both hands using a me-
chanical hand-held dynamometer, a valid tool for measuring overall muscle
strength [34,35].
Statistical Analysis
All analyses were conducted with SAS version 9.2 (SAS Institute, Inc.,
Cary, NC). Hours per week spent walking/biking to work and engaging in
leisure-time PA were summed to obtain total hours per week of PA. Par-
ticipants who met the US federal recommendation of at least 2.5 hours per
week of moderate-intensity PA in adults [36] were categorized as high PA,
whereas those reporting less than 2.5 hours per week were categorized as
low PA. Participants were categorized into low and high groups for mobility,
endurance, and handgrip strength based upon location either below or at/
above the median for HCT survivors and controls combined (median
mobility, 4.66 seconds; median endurance, 588.9 meters; median handgrip
strength, 27.5 kg).
Descriptive statistics are expressed as frequencies and percents or mean
 SE as appropriate. HCT survivors were grouped into 3 treatment groups
based on their HCT preparative regimen: total body irradiation (TBI) and
central nervous system (CNS) irradiation (TBI þ CNS), TBI but no CNS irra-
diation (TBI not CNS), and no TBI nor CNS irradiation (chemotherapy only).
Analysis of covariance models adjusted for multiple pairwise comparisons
by the post hoc Tukey-Kramer test were used to detect differences in PA,
ﬁtness, and cardiometabolic risk factors between the 3 treatment groups. All
analyses including data from sibling controls were implemented in SAS’s
GENMOD procedure using generalized estimating equations to account for
intrafamily correlation, with the default working correlation (indepen-
dence) and robust variance estimates. All adjusted comparisons used
multivariable linear regression models with adjustments for age, sex, and
race/ethnicity. As indicated, models were further adjusted for percent fat
mass, height, weight, and/or treatment when appropriate. Primary diag-
nosis, time since HCT, presence of growth hormone deﬁciency, and presence
of thyroid hormone deﬁciency were also considered as potential covariates
but were not included in ﬁnal models because their inclusion did not alter
the results in any substantive way. Adjusted means were evaluated at the
mean levels of covariates included in themodels. A 2-sided P value< .05was
considered to be statistically signiﬁcant, although because of the high
number of statistical tests carried out, those between .01 and .05 should be
viewed with caution.
RESULTS
On average, HCT survivors were slightly older, shorter,
and lighter than sibling controls, but body mass index (BMI)
was similar (Table 1). Controls and HCT survivors as a whole
had similar levels of PA, mobility, endurance, and strength, as
well as WC, HDL-C, and systolic and diastolic blood pressure
(Table 2). HCT survivors had greater percent fat mass, tri-
glycerides, LDL-C, and HOMA-IR and lower lean body mass
and IS than controls. These patterns differed somewhat
across the 3 treatment groups. Pairwise analyses revealed
that the TBI þ CNS group had lower mobility, strength, lean
Table 1
Characteristics of HCT Survivors and Sibling Controls
Characteristic Survivors (n ¼ 119) Controls (n ¼ 66) P Value
n (%) Mean  SE n (%) Mean  SE
Age at study, yr 27.4  .7 25.0  1.0 .02
Sex
Male 67 (56.3) 36 (54.6) .80
Female 52 (43.7) 30 (45.5)
Race/ethnicity*
White non-Hispanic 109 (91.6) 61 (92.4) .83
Other 10 (8.4) 5 (7.6)
Diagnosis







TBIþCNS 24 (20.2) NA
TBI not CNS 62 (52.1)
Chemotherapy onlyy 33 (27.7)
HCT type
Allogeneic 87 (73.1) NA
Autologous 32 (26.9)
Age at most recent HCT, yr 12.7  .6 NA
Height, cm 166.1  1.0 173.7  1.2 <.0001
Weight, kg 68.6  1.8 73.8  2.0 .04
BMI, kg/m2 24.6  .5 24.3  .5 .71
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; HOD, Hodgkin’s lymphoma; MDS, myelodysplastic
syndrome; NA, not applicable.
* White Hispanic, black, and other categories were collapsed for the comparison between survivors and controls.
y Some received other radiation before or after HCT: mantle/mediastinal (n ¼ 10 for HD), arm, orbit (n ¼ 2 for chloromas), temple (n ¼ 1 with history of
sarcoma and HCT for secondary AML), abdominal (n ¼ 1 for non-Hodgkin lymphoma).
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or both of the other treatment groups, particularly the
chemotherapy-only group. We also considered possible ef-
fects of HCT type (allogeneic versus autologous) and graft-
versus-host disease (3 categories: chronic only or chronic
plus acute, acute grades II and III, none or acute grade I).
There were no statistically signiﬁcant differences in PA,
ﬁtness, or cardiometabolic risk factors between HCT types or
between categories of graft-versus-host disease severity.Table 2
Physical Activity, Fitness, and Cardiometabolic Risk Factors in HCT Survivors and S
Risk Factors All Survivors (n ¼
119)
TBI þ CNS (n ¼ 24
Mean  SE P* Mean  SE P*
Physical activity/ﬁtness
Physical activity, h/wk 7.25  1.29 .62 6.16  1.73 .
Mobility, s 5.38  .26 .07 5.71 ± .24A .
Endurance, meters 583.1  29.8 .69 608.2  36.9 .
Handgrip strength, kg 30.5  2.1 .21 31.6 ± 3.2A .
Cardiometabolic risk factors
WC, cm 83.0  2.5 .62 82.3  3.9 .
Percent fat mass, % 36.0  1.2 <.0001 36.7  2.1 .
Lean body mass, kgy 42.7  .7 <.0001 39.3 ± 1.1A <.
Triglycerides, mg/dLz 181.3  19.4 .0001 268.1 ± 46.4A .
HDL-C, mg/dLz 43.1  1.7 .12 37.5 ± 2.2A .
LDL-C, mg/dL z 106.8  4.4 .007 115.4  6.3 .
Systolic blood pressure, mm Hgz 114.2  2.0 .25 119.6  3.7 .
Diastolic blood pressure, mm Hgz 68.7  1.6 .47 69.9  3.5 .
HOMA-IRz 2.95  .31 .0007 4.28  .61 .
IS, mg/kg/minz 9.98  .62 .03 7.76  1.03 .
All models adjusted for age, sex, and race/ethnicity.
For comparisons between TBI þ CNS, TBI not CNS, and chemotherapy-only groups,
different from each other (Tukey-Kramer test, P < .05). There were no signiﬁcant
* P value for comparison between survivors (or subgroup) and controls, on the
y Additional adjustment for height and weight.
z Additional adjustment for percent fat mass.Among HCT survivors, the high PA group had lower WC
than the low PA group (Table 3). Among controls, the high PA
group had lower diastolic blood pressure than the low PA
group. Among HCT survivors, the high endurance group had
lower WC and percent fat mass and greater IS than the low
endurance group (Table 4). There were no statistically sig-
niﬁcant differences between the low and high mobility
groups or between the low and high handgrip strength
groups within HCT survivors or controls (data not shown).ibling Controls
) TBI not CNS (n ¼ 62) Chemotherapy Only
(n ¼ 33)
Controls (n ¼ 66)
Mean  SE P* Mean  SE P* Mean  SE
73 7.71  .95 .61 8.04  1.73 .97 6.70  1.47
002 5.07 ± .32B .29 5.28 ± .43B .48 4.98  .29
11 585.7  72.9 .78 627.2  36.6 .77 591.9  39.1
17 24.9 ± 1.2A .02 34.4 ± 2.8B .05 32.8  2.4
82 81.9  4.7 .79 86.1  3.6 .13 82.1  3.3
002 34.2  2.1 .0007 36.5  1.7 .004 30.2  1.5
0001 42.0 ± .9AB <.0001 46.9 ± 1.0B .04 48.8  .4
002 179.3 ± 27.0AB .002 136.0 ± 21.7B .13 98.2  14.0
004 44.0 ± 2.3B .29 44.7 ± 2.6AB .74 45.9  1.8
001 102.2  5.9 .07 109.5  6.8 .03 93.5  3.9
32 115.7  2.9 .19 110.6  2.2 .13 116.4  2.3
27 68.3  1.9 .63 66.1  1.5 .75 67.7  1.6
0006 3.37  .52 .02 2.15  .35 .16 1.57  .38
003 9.61  .91 .08 11.3  .8 .51 11.9  .7
means within bolded rows that do not share the same letter are signiﬁcantly
differences within nonbolded rows.
basis of adjusted linear regression models.
Table 3
Cardiometabolic Risk Factors by Physical Activity Level in HCT Survivors and Sibling Controls















Mean  SE Mean  SE Mean  SE Mean  SE Pinteraction
WC, cm 88.6  3.1 81.9  2.5 .009 72.7  3.3 75.7  3.0 .21 .008
Percent fat mass, % 38.8  2.0 35.8  1.6 .07 24.3  3.3 25.5  2.6 .63 .28
Lean body mass, kgy 42.2  1.2 42.6  .9 .63 49.3  1.2 50.1  .6 .55 .55
Triglycerides, mg/dLz 221.2  51.3 192.2  41.0 .48 108.8  12.5 97.5  6.6 .38 .67
HDL cholesterol, mg/dLz 41.0  2.8 42.4  2.2 .54 40.8  3.4 44.8  2.7 .19 .71
LDL cholesterol, mg/dLz 116.8  9.3 114.1  7.3 .71 94.8  6.5 90.6  3.2 .63 .68
Systolic blood pressure, mm Hgz 118.0  3.6 114.3  2.9 .21 113.3  3.0 111.2  2.1 .44 .24
Diastolic blood pressure, mm Hgz 71.8  2.7 71.1  2.2 .77 66.6  1.3 61.6  .8 .02 .30
HOMA-IRz 2.82  1.69 3.19  1.33 .79 2.38  .61 1.51  .23 .11 .48
IS, mg/kg/minz 8.19  1.37 9.46  1.07 .26 10.3  1.4 12.2  .9 .18 .70
All models adjusted for age, sex, and race/ethnicity.
* Additional adjustment for treatment (HCT preparative regimen) in all models of survivors.
y Additional adjustment for height and weight.
z Additional adjustment for percent fat mass.
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survivor/control status and PA/ﬁtness level for each car-
diometabolic risk factor. As depicted by the interaction plots
in Figure 1 and displayed in the rightmost column of Tables 3
and 4, differences in WC between low and high PA and dif-
ferences in WC, systolic blood pressure, and IS between low
and high endurance depended on survivor/control status (all
Pinteraction < .05). In general, HCT survivors had larger differ-
ences in WC, systolic blood pressure, and IS at the higher PA/
endurance levels compared with controls. There was no such
evidence of effect modiﬁcation by survivor/control status for
the other risk factors examined (all Pinteraction > .05).DISCUSSION
This study found that endurance, to a greater degree than
mobility, handgrip strength, or self-reported PA, was asso-
ciated with certain cardiometabolic risk factors in HCT sur-
vivors. Speciﬁcally, high endurance was associated with
lower WC and percent fat mass and greater IS among HCT
survivors. Prior studies of healthy individuals have indicated
that cardiorespiratory endurance is more strongly associated
with obesity [37-39] and IS [38,40] than measures of PA or
muscle strength.Table 4







Mean  SE Mean  SE
WC, cm 87.8  2.5 77.8  2.6 .0
Percent fat mass, % 39.4  1.7 33.6  1.8 .0
Lean body mass, kgy 40.4  1.1 41.7  1.0 .2
Triglycerides, mg/dLz 217.0  45.6 160.1  44.4 .2
HDL cholesterol, mg/dLz 43.0  2.2 45.0  2.1 .3
LDL Cholesterol, mg/dLz 112.8  9.0 118.0  8.2 .5
Systolic blood pressure, mm Hgz 120.3  3.2 114.6  3.1 .0
Diastolic blood pressure (mm Hg) z 71.5  2.6 71.2  2.5 .9
HOMA-IRz 3.63  1.79 1.80  1.60 .2
IS, mg/kg/minz 7.42  1.14 10.9  1.0 .0
All models adjusted for age, sex, and race/ethnicity.
* Additional adjustment for treatment (HCT preparative regimen) in all models
y Additional adjustment for height and weight.
z Additional adjustment for percent fat mass.Similar comparisons between PA and ﬁtness measures
have not been previously made in CCS. However, a recent
16-week home-based exercise intervention involving 17 16-
to 30-year-old survivors of childhood acute lymphoblastic
leukemia without HCT resulted in signiﬁcant improvements
in WC, waist-to-hip ratio, percent body fat, fasting plasma
insulin, and HOMA-IR, while simultaneously improving VO2
max, maximal work load, and muscle strength [41]. Weight,
BMI, triglycerides, total cholesterol, LDL-C, HDL-C, and
fasting plasma glucose remained unchanged and the effect
on blood pressure was variable. Results were also mixed in
a larger study of adult survivors of childhood acute
lymphoblastic leukemia (6 of 117 underwent HCT); greater
PA energy expenditure was associated with lower percent
body fat but not with BMI, WC, HOMA-IR, or metabolic
syndrome [42].
In a study of 2300 HCT survivors, those with serious
cardiovascular disease and those with only hypertension or
diabetes were less likely to meet recommended PA levels
[24]. A smaller study of 26 HCT and 48 non-HCT survivors
found that a history of HCT was a signiﬁcant risk factor for
having 2 or cardiometabolic traits, as well as for meeting
criteria for metabolic syndrome, but these risks were not








Mean  SE Mean  SE Pinteraction
001 76.7  2.3 79.3  1.5 .30 .001
008 30.1  3.0 29.3  1.1 .79 .17
5 46.2  1.8 49.0  .9 .20 .77
1 91.9  9.4 107.9  7.0 .26 .10
7 39.5  3.0 41.8  1.3 .47 .88
2 91.2  6.0 90.8  3.3 .95 .90
8 109.9  2.1 113.7  .9 .15 .02
2 62.9  1.7 62.5  1.0 .83 .80
7 2.05  .19 1.59  .10 .05 .24
01 14.4  1.3 13.5  .6 .49 .02
of survivors.
Figure 1. Survivor/control status  PA level (low versus high PA) interaction plot for WC and survivor/control status  endurance level (low versus high endurance)
interaction plots for WC, systolic blood pressure, and IS. These plots assess whether the difference in WC between high and low PA was the same for HCT survivors
and controls and whether the differences in WC, systolic blood pressure, and IS between high and low endurance were the same for HCT survivors and controls.
M.E. Slater et al. / Biol Blood Marrow Transplant 21 (2015) 1278e12831282agreement with previous ﬁndings [12,43-45], HCT survivors
in the current study who had CNS irradiation as a part of
their HCT preparative regimen had lower mobility, strength,
and lean body mass and appeared to be at higher risk of
dyslipidemia (low HDL-C and high triglycerides and/or LDL-
C) when compared with 1 or more of the groups who did not
receive CNS irradiation.
Results from our interaction tests implied that in-
terventions, especially those that increase endurance, might
work more effectively to decrease and/or maintain WC in
HCT survivors than in controls. The interaction models also
suggested that increases in endurance may lead to more
effective improvement or maintenance of systolic blood
pressure and IS, whereas increases in mobility may lead to
more effective improvement or maintenance of triglyceride
levels in HCT survivors compared with controls. No known
prior studies have made similar types of comparisons;
however, it was previously suggested that there may be a
threshold effect for the PA-insulin resistance relationship
(based on systolic blood pressure or body size) or that the
relationship is more subtle and not recognized in leaner
adolescents [46]. These new ﬁndings support further inves-
tigation into prospective interventions in HCT survivors that
focus on improving endurance as a possible way of amelio-
rating cardiometabolic complications.
It is possible that we lacked power to detect clinically
signiﬁcant differences for some of the risk factors examined
in this study, and conversely, some of the ﬁndings could have
been due to chance. Further research in this population is
needed to conﬁrm our results. Using objective measures of
PA/ﬁtness, such as the ﬁtness tests utilized in this study, is
recommended over the use of less reliable self-report mea-
sures. Direct measures of abdominal subcutaneous and
visceral fat mass (via computed tomography), vascular
health (ie, endothelial-dependent dilation, intimamedia
thickness, carotid artery cross-sectional compliance and
distensibility), and knee extension strength were notavailable for a majority of participants in this study, but they
may be important to consider in future investigations. Lastly,
wewere not able to check for possible systematic differences
between participants and nonparticipants because informa-
tion on nonparticipants was not available.
This study serves to ﬁll important gaps in knowledge
regarding associations between PA/ﬁtness and car-
diometabolic risk factors among CCS with a history of HCT.
Although it is not new to ﬁnd an association between PA/
ﬁtness and cardiometabolic risk factors in healthy pop-
ulations, results suggesting that these relationships are
stronger in HCT survivors than in controls are of importance,
as they suggest that PA could serve as a tangible target in
mitigating the already high cardiometabolic risks of many
HCT survivors. Sustainable PA programs focused on
improving endurance and tailored to HCT survivors are
worth exploring as a means of reducing early morbidity and
mortality.
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